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Purpose. Fludarabine is a key component of several reduced-intensity conditioning regimens for 
hematopoietic cell transplantation (HCT).  Shortly after reduced-intensity conditioning, the 
percent of donor natural killer (NK) cells has been associated with progression-free survival. 
Insufficient suppression of the recipient’s NK cells by fludarabine may lead to lower donor 
chimerism; however, the effect of fludarabine upon NK cells is poorly understood.  Thus, in 
purified human NK cells we evaluated the uptake and activation of fludarabine to its active 
metabolite, fludarabine triphosphate (F-ara-ATP), and assessed the degree of interindividual 
variability in F-ara-ATP accumulation.  Methods. Intracellular F-ara-ATP was measured in 
purified NK cells isolated from healthy volunteers (n = 6) after ex vivo exposure to fludarabine.  
Gene expression levels of the relevant transporters and enzymes involved in fludarabine uptake 
and activation were also measured in these cells.  Results. F-ara-ATP accumulation (mean ± 
s.d.) was 6.00 ± 3.67 pmol/1x106 cells/4 hours, comparable to average levels previously 
observed in CD4+ and CD8+ T-lymphocytes.  We observed considerable variability in F-ara-ATP 
accumulation and mRNA expression of transporters and enzymes relevant to F-ara-ATP 
accumulation in NK cells from different healthy volunteers.  Conclusions. Human NK cells have 
the ability to form F-ara-ATP intracellularly and large interindividual variability was observed in 
healthy volunteers.  Further studies are needed to evaluate whether F-ara-ATP accumulation in 
NK cells are associated with apoptosis and clinical outcomes. 




The use of the purine nucleoside analog fludarabine in allogeneic hematopoietic cell 
transplant (HCT) conditioning regimens has dramatically increased over the past 10 years.  
Fludarabine, administered as its monophosphate form over a wide dosage range of 90-250 
mg/m2, is a key component of myeloablative, reduced-intensity, and nonmyeloablative 
conditioning regimens [1].  Reduced-intensity and nonmyeloablative conditioning regimens do 
not completely ablate the recipient’s immune system, therefore resulting in a temporary state of 
mixed chimerism in which donor and recipient hematopoietic cells co-exist in the recipient.  
Chimerism is typically evaluated within various blood cell subsets [e.g., CD3+, natural killer 
(NK) and granulocytes], and higher rates of donor chimerism early after HCT have been 
associated with improved clinical outcomes [2-4].  Current research has focused upon identifying 
the optimal cell population to monitor for donor chimerism levels.  Recent clinical studies 
suggest that higher early donor chimerism in NK cells is associated with lower relapse rates and 
improved progression-free survival [5-8].  NK cells are an important component of innate 
immunity and are characterized by expression of the CD56 antigen and a lack of expression of 
the T-lymphocyte marker CD3.  It is critical to gain an improved understanding of predictors of 
NK donor chimerism in recipients of fludarabine-based reduced-intensity and nonmyeloablative 
conditioning regimens. 
Fludarabine must undergo active intracellular transport and metabolism to form 
fludarabine triphosphate (F-ara-ATP), its active metabolite that inhibits ribonucleotide reductase 
and DNA polymerase and ultimately leads to cellular apoptosis in both actively dividing and 
resting cells [9].  Fludarabine (9-β-D-arabinofuranosyl-2-fluoroadenine) is administered as the 
monophosphate prodrug and is rapidly dephosphorylated in plasma to fludarabine by serum 
phosphatase and ecto-5’-nucleotidase (CD73) [9].  Intracellular uptake of fludarabine is mediated 
by several nucleoside transporters, including the nitrobenzylthioinosine (NBMPR)-sensitive 
human equilibrative nucleoside transporter 1 (hENT1), the NBMPR-insensitive human 
equilibrative nucleoside transporter 2 (hENT2), and the human concentrative nucleoside 
transporter 3 (hCNT3) [9, 10].  Once inside the cell, fludarabine is sequentially phosphorylated 
to the monophosphate (F-ara-AMP), diphosphate (F-ara-ADP), and triphosphate (F-ara-ATP) 
forms by deoxycytidine kinase (dCK), adenylate kinase (AK), and nucleoside diphosphate kinase 
(NDK), respectively [11].  F-ara-AMP can also be dephosphorylated to fludarabine by 5’-
nucleotidase (CN-II) and deoxynucleotidase-1 (dNT-1).  The expression of these transporters and 
enzymes, along with their contribution to accumulation and formation of intracellular F-ara-
ATP, has yet to be evaluated in NK cells.   
Fludarabine administration has been shown to deplete CD4+ and CD8+ T-lymphocytes; 
however, there is less information regarding its pharmacological action on NK cells [12-14].  
Interindividual differences in the ability of recipient NK cells to uptake and activate F-ara-ATP 
may contribute to variability in recipient NK cell survival.  Inadequate suppression of recipient 
NK cells could lead to low donor NK cell chimerism levels, which have been associated with a 
higher risk of rejection and worse progression-free survival after fludarabine-containing 
conditioning regimens [6].  Thus, identifying risk factors for low donor NK chimerism, such as 
low F-ara-ATP accumulation in NK cells, is of keen interest.  We sought to determine the 
feasibility of evaluating F-ara-ATP accumulation in NK cells ex vivo.  Specifically, our goal was 
to isolate enough purified NK cells from apheresis products obtained from healthy volunteers to 
characterize the disposition and accumulation of F-ara-ATP in these NK cells.  This allowed us 
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to test two hypotheses: first, that NK cells form F-ara-ATP intracellularly, and second, that there 
is considerable interindividual variability in F-ara-ATP accumulation rates.  We also evaluated 
the interindividual variability in the mRNA expression levels of the key transporters (hENT1, 
hENT2, and hCNT3) and enzymes (dCK, CN-II, and dNT-1) important in fludarabine uptake 
and activation.  These studies provide the first evidence that characterizing the intracellular 
disposition of fludarabine in human NK cells may help to identify risk factors of graft rejection 
or progression-free survival, and ultimately result in improved clinical outcomes. 
 
MATERIAL AND METHODS 
 
Isolation of NK Cells from Healthy Volunteers 
Prior to study procedures, written consent was obtained using forms approved by the 
Institutional Review Board of the Fred Hutchinson Cancer Research Center.  Six healthy 
volunteers donated a mononuclear-enriched apheresis product.  The median age of the volunteers 
was 32 years (range: 29 – 51 years); five males and one female; four Caucasian and two 
Hispanic.  No information regarding past medical history or concomitant medications was 
available.  The apheresis product was first CD3-depleted using anti-CD3 magnetic microbeads to 
remove T-lymphocytes and then NK cells were purified from the CD3-depleted fraction using 
anti-CD56 magnetic microbeads (Miltenyi Biotec Inc., Auburn, CA) and an AutoMACS™ 
automatic magnetic cell sorter (Miltenyi Biotec Inc.) according to the manufacturer’s 
recommendations.  NK cell purities were 91.0 ± 4.9% for the isolations. 
 
Fludarabine Triphosphate Accumulation in NK Cells 
The measurement of F-ara-ATP accumulation was initiated in each purified NK cell 
population within 2 hours of cell isolation.  Using a procedure optimized for CD4+ and CD8+ 
cells [15], 1x106 NK cells were incubated in fludarabine (5 μM) in RPMI 1640 media (not 
containing phenol red) supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) 
antibiotic/antimycotic for 4 hours at 37°C in 5% CO2.  This concentration is in the range of the 
peak fludarabine plasma concentration (3 µM) after fludarabine monophosphate administration 
of 30 mg/m2/day, the dose used in some nonmyeloablative conditioning regimens [16, 17].  
Incubations were conducted in duplicate, and F-ara-ATP concentration was quantitated using the 
LC-MS method we have described previously [15, 18].  The units for all F-ara-ATP 
accumulation rates were pmol/1x106 cells/4 hours. 
 
Gene Expression Analysis 
Total RNA was extracted from purified NK cells from healthy volunteers using the gene 
expression protocol we have described previously [15].  Gene-specific TaqMan® Gene 
Expression Assays (Applied Biosystems, Foster City, CA) were used to quantitate mRNA 
expression of the following key transporters: hENT1, hENT2, hCNT3, dCK, CN-II, and dNT-1 
relative to an internal endogenous control β-glucuronidase (GUS) on a 7900HT Fast Real-Time 
PCR System (Applied Biosystems) [15].  Samples were performed in triplicate and the delta-
delta threshold cycle (CT) method was used to provide an estimation of relative gene expression 
(arbitrary units) as described previously [15]. 
 
Woodahl et al.  Fludarabine Uptake and Activation in NK Cells 
5 
Statistical Analysis 
Student's two-sided t test was used to evaluate differences between two sets of data.  P 




F-ara-ATP Accumulation in NK Cells 
We were able to purify a sufficient number NK cells to allow for quantitation of 
intracellular F-ara-ATP accumulation in all six participants.  Median cell yields after NK cell 
isolation in healthy volunteers was 1.69×107 (range:  1.09×107 – 1.91×107).  Substantial 
interindividual variability was observed in F-ara-ATP accumulation in the purified NK cells 
from healthy volunteers (Figure 1).  Following incubation with 5 µM fludarabine, the mean (± 
s.d.) F-ara-ATP accumulation was 6.00 ± 3.67 pmol/1x106 cells/4 hours (Table 1).  F-ara-ATP 
accumulation rates ranged from 1.44 – 11.9 (min – max) pmol/1x106 cells/4 hours, which is 
represents an 8.3-fold variability.  The replicates were within 87-100% of each other. 
 
Gene Expression in NK Cells 
 The level of mRNA expression of the key transporters and enzymes involved in 
fludarabine uptake and subsequent formation of F-ara-ATP was measured relative to an 
endogenous control (GUS) (Table 1).  We observed large interindividual variability in gene 
expression; variability was largest in the expression of hCNT3 (47-fold), followed by hENT2 
(9.3-fold), dCK (8.4-fold), hENT1 (6.3-fold), CN-II (4.4-fold), and smallest variability in dNT-1 
(1.7-fold). 
 
F-ara-ATP in NK Cells Compared to T-Lymphocytes 
Previously, we have reported the F-ara-ATP accumulation and corresponding gene 
expression pattern in CD4+ and CD8+ T-lymphocytes isolated from healthy volunteers and HCT 
recipients [15].  We compared the differences in F-ara-ATP accumulation and gene expression in 
the T-lymphocytes and NK cells isolated from healthy volunteers (Table 1).  We were able to 
collect both NK cells and T-lymphocytes from three of the donors in this study; however, we 
were only able to obtain either NK cells or T-lymphocytes from the remaining donors.  Average 
F-ara-ATP accumulation in NK cells was not significantly different from that seen in CD4+ and 
CD8+ T-lymphocytes.  However, the interindividual variability we observed in NK cells from 
healthy volunteers (8.3-fold) was greater than the variability we previously reported in CD4+ and 
CD8+ T-lymphocytes (1.6- and 1.9-fold, respectively) [15].  We also observed differences in 
mRNA expression between NK cells and T-lymphocytes.  In particular, hENT1 was significantly 
higher in NK cells than in CD8+ cells (p < 0.005).  NK cells displayed significantly lower hENT2 
gene expression in both CD4+ (p < 0.05) and CD8+ (p < 0.001) cells. 
 
DISCUSSION 
Our studies are the first to demonstrate that NK cells have the ability to uptake 
fludarabine and activate it to F-ara-ATP, which is a novel finding in that there is a general 
impression that NK cells are resistant to fludarabine.  Thus, these reported data are a critical first 
step to understanding the effects of fludarabine upon NK cells.  We observed considerable 
interindividual variability in the accumulation of F-ara-ATP in NK cells as well as in the mRNA 
expression of the key genes involved in fludarabine uptake and activation.  The overall level of 
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F-ara-ATP accumulation in NK cells is similar to what we observed previously in CD4+ and 
CD8+ T-lymphocytes in healthy volunteers [15]; however, the degree of variability appears 
larger in NK cells.  Our method of measuring F-ara-ATP accumulation has the potential to be 
used to evaluate interindividual variability in patients receiving fludarabine-containing 
conditioning regimens prior to receiving allogeneic HCT, and could serve as a possible predictor 
of subsequent donor NK chimerism. 
Currently, there are few studies examining the pharmacokinetic and pharmacodynamic 
effects of fludarabine upon NK cells, and seemingly contradictory results have been reported.  
Early in vitro and animal studies suggest that NK cells do not require proliferation for their 
activity and that fludarabine exposure actually enhanced NK cell activity [12, 13].  However, a 
recent study in 34 chronic lymphocytic leukemia patients suggests that initial administration of 
fludarabine (doses not described) led to a decrease in the number of CD56+-expressing cells after 
3 months [14].  Further fludarabine administration from 3 to 6 months led to a slight increase in 
NK counts; however, these counts still did not return to the baseline levels observed prior to 
fludarabine administration [14].  In our study, we have shown that purified human NK cells have 
the ability to uptake fludarabine and form F-ara-ATP, its active cytotoxic metabolite. The 
average F-ara-ATP accumulation in NK cells we observed was comparable to that seen in CD4+ 
and CD8+ T-lymphocytes (Table 1); and this amount of F-ara-ATP accumulation in T-
lymphocytes was sufficient to lead to loss of cell viability after 24 hour incubation with 
fludarabine [15].  Future studies should address if F-ara-ATP accumulation rates are associated 
with apoptosis in human NK cells.   
Average F-ara-ATP accumulations in healthy volunteers were not significantly different 
between NK cells and CD4+ and CD8+ T-lymphocytes, which were reported previously (Table 1) 
[15].  However, we did observe substantially greater interindividual variability in F-ara-ATP 
accumulation in NK cells compared to T-lymphocytes [15].  A limitation is that only 
demographic data (i.e., no information regarding past medical history or concomitant 
medications) was available on these healthy volunteers.  In our previous report, we also 
demonstrated that variability is greater in T-lymphocytes isolated from HCT patients than from 
healthy volunteers [15].  If this trend is similar in NK cells, we would expect even larger 
interindividual variability in F-ara-ATP accumulation in NK cells from HCT patients.  Large 
interindividual differences in F-ara-ATP accumulation in recipient NK cells may lead to variable 
killing of those cells after fludarabine administration and affect donor NK cell chimerism levels.  
Higher donor chimerism of NK cells at day-14 and day-28 post-nonmyeloablative HCT, more so 
than that of CD4+ or CD8+ T-lymphocytes, has been associated with lower rejection rates and 
improved progression-free survival [5, 6].  Therefore, overall recipient and donor NK cell counts 
during the first 4-5 weeks after fludarabine treatment may be clinically important; and 
insufficient suppression of recipient NK cells prior to HCT may be a critical factor leading to 
low donor chimerism early post-transplant.  Successful nonmyeloablative conditioning with 
fludarabine may correlate with reduced functionality and survival of recipient NK cells, which 
would in turn are associated with improved progression-free survival.  Therefore, it may be 
desirable to quantitate the recipient’s NK cell F-ara-ATP accumulation prior to conditioning, and 
adjust fludarabine doses accordingly to maximize the suppression of recipient NK cells such that 
optimal early donor NK chimerism can be achieved. 
Ideally, future studies would evaluate the association between F-ara-ATP accumulation 
in NK cells and clinical response.  However, a major difficulty towards such studies is obtaining 
sufficient number of NK cells to measure F-ara-ATP accumulation from HCT recipients.   Even 
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with our highly sensitive analytical method for F-ara-ATP quantitation, a relatively large number 
of NK cells (i.e. 1.25x105 cells/incubate) must be obtained from HCT recipients to measure F-
ara-ATP accumulation ex vivo.  We were able to isolate sufficient quantities from NK cells from 
apheresis products, but this method may not be practical for HCT recipients prior to fludarabine 
administration.  The number of NK cells isolated from apheresis products was almost 2-fold less 
than the number of CD4+ or CD8+ T-lymphocytes we were able to isolate previously from the 
same amount of apheresis product [15].  Also in our previous study, we compared F-ara-ATP 
accumulation in T-lymphocytes isolated from apheresis products donated by healthy volunteers 
and peripheral blood draws (60 mL) donated by HCT patients.  Our median cell yields after 
isolation of CD4+ and CD8+ T-lymphocytes were almost a log of magnitude less in HCT patients 
compared to healthy volunteers [15].  Thus, it is very likely that the number of NK cells one can 
obtain from patients awaiting HCT will not be sufficient to quantitate ex vivo F-ara-ATP 
formation.  Therefore, more sensitive methods (e.g. immunoassay) requiring less cell numbers 
may need to be developed to apply to future studies investigating the relationship between F-ara-
ATP accumulation in NK cells and clinical response. The identification of surrogates for F-ara-
ATP accumulation rate may also be of benefit in determining whether the efficacy (e.g., 
immunosuppression) and toxicity of fludarabine can be predicted in HCT recipients. 
We observed significant interindividual variability in the gene expression of the 
transporters and enzymes involved in fludarabine uptake and subsequent activation to F-ara-
ATP.    It would be interesting to see whether expression levels of these genes are related to the 
ability of NK cells to form F-ara-ATP.  Unfortunately, the number of healthy volunteers in our 
study is too small to allow for meaningful statistical analyses examining such a relationship.  In a 
previous study, we did not find an association between F-ara-ATP accumulation and gene 
expression in CD4+ and CD8+ T-lymphocytes isolated from HCT patients [15].  Other studies 
have also found that mRNA expression is not a good marker for activity of the enzymes and 
transporters relevant in fludarabine triphosphate uptake and activation [10, 19, 20].  As mRNA 
expression levels do not always correlate with protein expression and activity, additional studies 
directly evaluating protein expression and activities of the relevant transporters and enzymes 
may be useful in identifying potential surrogate markers of F-ara-ATP accumulation in NK cells.   
In conclusion, we demonstrated that NK cells form F-ara-ATP and have observed 
significant interindividual variability in F-ara-ATP accumulation in NK cells isolated from 
healthy volunteers.  Further work is needed to directly evaluate the pharmacodynamic 
relationships between F-ara-ATP accumulation in NK cells with apoptosis ex vivo and clinical 
outcomes in vivo.  Variable fludarabine uptake and activation in recipient NK cells may lead to 
variable clinical outcomes in HCT patients, particularly affecting the levels of donor NK cell 
chimerism, the rate of engraftment, and progression-free survival.  Understanding interindividual 
variability in F-ara-ATP accumulation in NK cells may help to optimize fludarabine-containing 
conditioning regimens prior to HCT and enhance the therapeutic outcomes for these patients.
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Figure 1.  F-ara-ATP Accumulation in Purified Human NK Cells.  Range of F-ara-ATP 
accumulations in NK cells (z) isolated from healthy volunteers (n = 6).  Solid line indicates the 
mean value (pmol/1x106 cells/4 hours). 
 




Table 1. Comparison of F-ara-ATP Accumulation and Gene Expression in NK Cells and 
CD4+ and CD8+ T-Lymphocytes From Healthy Volunteers 
 NK Cells 
(n = 6) 
CD4+ Cellsa
(n = 12) 
CD8+ Cellsa
(n = 12) 
    
F-ara-ATP Accumulation pmol/1x106 cells/4 hours 
 (Range: min – max) 
    
 6.00 ± 3.67 7.74 ± 1.02 8.66 ± 1.92 
 (1.44 – 11.9) (6.0 – 9.5) (6.4 – 12.4) 
    
Gene Expressionb arbitrary units 
 (Range: min – max) 
    
hENT1 15.1 ± 10.0 16.6 ± 30.6 2.42 ± 1.76**
 (5.38 – 34.1) (4.32 – 92.0) (0.920 – 6.11) 
hENT2 18.5 ± 15.9 119 ± 85* 99.8 ± 40.9***
 (5.05 – 46.9) (42.2 – 279) (45.4 – 164) 
hCNT3 3.67 ± 5.30 0.685 ± 1.22 0.359 ± 0.260 
 (0.275 – 13.0) (0.118 – 3.68) (0.032 – 0.802) 
dCK 947 ± 637 1423 ± 475 1908 ± 1269 
 (212 – 1778) (778 – 2124) (983 – 4985) 
CN-II 506 ± 200 593 ± 220 633 ± 240 
 (172 – 751) (383 – 1059) (483 – 1175) 
dNT-1 113 ± 26 72.7 ± 66.0 102 ± 93 
 (89.8 – 151) (12.2 – 182) (22.0 – 264) 
a Data previously reported in [15]. 
b Significant difference observed between NK cells and T-lymphocytes: * p < 0.05; ** p < 
0.005; *** p < 0.001. 
